Research and Markets: Kuwait Pharmaceuticals and Healthcare Report Q3 2009

DUBLIN--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/research/70376f/kuwait_pharmaceuti) has
announced the addition of the "Kuwait Pharmaceuticals and Healthcare Report Q3
2009" report to their offering.

Kuwait Pharmaceuticals and Healthcare Report provides industry professionals and
strategists, corporate analysts, pharmaceutical associations, government
departments and regulartory bodies with independent forecasts and competitive
intelligence on Kuwait's pharmaceutical and healthcare industry

Kuwait's pharmaceutical market is small in regional terms. Combined sales of
over-the-counter (OTC) and prescription drugs reached a total of US$377mn in
2008, and we expect this to reach US$462mn by 2013 - representing a compound
annual growth rate (CAGR) of 4.17% in US dollar terms.

Pharmaceutical spending will account for 0.27% of GDP, with per capita
expenditure at US$136 by the end of the forecast period. We expect growth to be
driven by the strong bias toward patented drugs, which still dominate the
market.

With little or no enforced incentives for prescribers or dispensers to
substitute for generics where possible, this looks likely to continue in the
medium term. However, we note that import policies in the region have all been
affected by unfavourable currency fluctuations against the euro when procuring
EU medicines. We note that the Kuwaiti government is not actively encouraging a
domestic manufacturing industry, which restricts choices on imports and in
addition means the country is heavily reliant on those medicines.

BMI's Burden of Disease Database (BoDD) reveals that the number of
disability-adjusted life years (DALYs) lost to communicable diseases in Kuwait
will decrease from 29,836 in 2008 to 24,888 by 2030. Meanwhile, the DALYs lost
to non-communicable disease will rise from 190,740 in 2008 to 258,306 by 2030.
The main driver for this growth is attributed to the rise in obesity and
obesity-related disorders including hypertension, diabetes, and cardiovascular
disease.

We note that chronic conditions pose a significant burden on healthcare services
and directly lead to a rise in prescription medication spending. This makes the
patented drug market in these therapeutic areas particularly attractive to
multinational drugmakers looking for new export destinations in the Middle East.
Generic drugs are slowly gaining market share, though government policy on
substitution needs to be drafted and implemented to encourage further growth in
this sector.

Key Topics Covered:

* Executive Summary
* SWOT Analysis
* Pharmaceutical Business Environment Ratings
* Kuwait - Market Summary
* Regulatory Regime
* Industry Developments
* Industry Forecast Scenario
* Competitive Landscape
* Company Profiles
* Country Snapshot: Kuwait Demographic Data
* BMI Forecast Modelling

For more information visit
http://www.researchandmarkets.com/research/70376f/kuwait_pharmaceuti

Research and Markets
Laura Wood
Senior Manager
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716
press@researchandmarkets.com

Copyright Business Wire 2009